Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 2/20 | 0.49 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.40 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.40 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.40 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.40 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.40 |
| ▸ | LIPE | Q05469 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13451380 | 0.85 | BRD4 (0.47) | BRD4EPHX1L3MBTL1THRBATM | |
| SCHEMBL8286682 | 0.84 | BRD4 (0.49) | BRD4EPHX1EPHX2L3MBTL1THRB | |
| SCHEMBL2464935 | 0.83 | L3MBTL1 (0.42) | BRD4ALOX5EPHX2L3MBTL1THRB | |
| SCHEMBL14827431 | 0.82 | BRD4 (0.51) | BRD4EPHX1L3MBTL1THRBATM | |
| SCHEMBL771084 | 0.82 | BRD4 (0.48) | BRD4EPHX1L3MBTL1THRBATM | |
| SCHEMBL1267275 | 0.82 | GAA (0.61) | BRD4L3MBTL1THRBATMGAA | |
| SCHEMBL25613273 | 0.81 | BRD4 (0.47) | BRD4EPHX1L3MBTL1THRBATM | |
| SCHEMBL13451670 | 0.81 | BRD4 (0.50) | BRD4EPHX1L3MBTL1THRBATM | |
| Hydrochloric Acid SCHEMBL28522243 | 0.81 | BRD4 (0.50) | BRD4EPHX1L3MBTL1THRBATM | |
| SCHEMBL13498638 | 0.81 | BRD4 (0.47) | BRD4EPHX1L3MBTL1THRBATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220274957-A1 | BENZIMIDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-09-01 | — | — | US | disclosed |
| US-11254655-B2 | Benzimidazole-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-02-22 | — | — | US | disclosed |
| US-20200283408-A1 | BENZIMIDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-09-10 | — | — | US | disclosed |
| US-10696656-B2 | Benzimidazole-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-06-30 | — | — | US | disclosed |
| US-10696656-B2 | Benzimidazole-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-06-30 | — | — | US | disclosed |
| US-20190152951-A1 | BENZIMIDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-05-23 | — | — | US | disclosed |
| US-20190152951-A1 | BENZIMIDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-05-23 | — | — | US | disclosed |
| US-10233172-B2 | Benzimidazole-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-03-19 | — | — | US | disclosed |
| US-10233172-B2 | Benzimidazole-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-03-19 | — | — | US | disclosed |
| US-20180237420-A1 | BENZIMIDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-08-23 | — | — | US | disclosed |
| US-7256294-B2 | Crystalline form of a benzimidazole-carboxamide medicinal compound | THERAVANCE, INC. (US) | 2007-08-14 | — | — | US | disclosed |
| US-7256294-B2 | Crystalline form of a benzimidazole-carboxamide medicinal compound | THERAVANCE, INC. (US) | 2007-08-14 | — | — | US | disclosed |
| US-7205434-B2 | Sulphonamido-substituted bridged bicycloalkyl derivatives having a substitute on the bridgehead position; nonpeptidic compounds to treat or prevent Alzheimer's Disease by modulating the processing of amyloid precursor proteins by the putative gamma-secretas to arrest the production of beta-amyloid | MERCK SHARP & DOHME LTD. (GB) | 2007-04-17 | — | — | US | disclosed |
| US-7205434-B2 | Sulphonamido-substituted bridged bicycloalkyl derivatives having a substitute on the bridgehead position; nonpeptidic compounds to treat or prevent Alzheimer's Disease by modulating the processing of amyloid precursor proteins by the putative gamma-secretas to arrest the production of beta-amyloid | MERCK SHARP & DOHME LTD. (GB) | 2007-04-17 | — | — | US | disclosed |
| US-20060270854-A1 | Crystalline form of a benzimidazole-carboxamide medicinal compound | THERAVANCE, INC. | 2006-11-30 | — | — | US | disclosed |
| US-20060270854-A1 | Crystalline form of a benzimidazole-carboxamide medicinal compound | THERAVANCE, INC. | 2006-11-30 | — | — | US | disclosed |
| US-20060270854-A1 | Crystalline form of a benzimidazole-carboxamide medicinal compound | THERAVANCE, INC. | 2006-11-30 | — | — | US | disclosed |
| WO-2006127815-A2 | BENZIMIDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | THERAVANCE, INC. (US) | 2006-11-30 | — | — | WO | disclosed |
| WO-2006127815-A2 | BENZIMIDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | THERAVANCE, INC. (US) | 2006-11-30 | — | — | WO | disclosed |
| US-20060270652-A1 | Benzimidazole-carboxamide compounds as 5-HT4, receptor agonists | THERAVANCE, INC. | 2006-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10233172-B2 | Benzimidazole-carboxamide compounds as 5-HT4 receptor agonists | HTR4, HTR1A, HTR5A | BRD4 115/4885ALOX5 944/4885EPHX1 1521/4885 |
| US-20180237420-A1 | BENZIMIDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | HTR4, HTR1A, HTR5A | BRD4 115/4885ALOX5 944/4885EPHX1 1521/4885 |
| US-20200283408-A1 | BENZIMIDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | HTR4, HTR1A, HTR5A | BRD4 115/4885ALOX5 944/4885EPHX1 1521/4885 |
| US-11254655-B2 | Benzimidazole-carboxamide compounds as 5-HT4 receptor agonists | HTR4, HTR1A, HTR5A | BRD4 115/4885ALOX5 944/4885EPHX1 1521/4885 |
| US-10696656-B2 | Benzimidazole-carboxamide compounds as 5-HT4 receptor agonists | HTR4, HTR1A, HTR5A | BRD4 115/4885ALOX5 944/4885EPHX1 1521/4885 |
| US-20220274957-A1 | BENZIMIDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | HTR4, HTR1A, HTR5A | BRD4 115/4885ALOX5 944/4885EPHX1 1521/4885 |
| US-20060270652-A1 | Benzimidazole-carboxamide compounds as 5-HT4, receptor agonists | HTR4, HTR1A, HTR5A | BRD4 110/4885ALOX5 818/4885EPHX1 1626/4885 |
| US-20190152951-A1 | BENZIMIDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | HTR4, HTR1A, HTR5A | BRD4 115/4885ALOX5 944/4885EPHX1 1521/4885 |
| US-20060270854-A1 | Crystalline form of a benzimidazole-carboxamide medicinal compound | HTR4, HTR5A, HTR1A | BRD4 178/4885ALOX5 538/4885EPHX1 3643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.